Comparing standard surveillance imaging to symptom based imaging in glioblastoma

Surveillance versus symptom-directed magnetic resonance imaging in glioblastoma: Phase 3 randomized controlled trial (MAGNOLIA) - MANGOLIA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089633

Enrollment

240

Registered

2025-06-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G94- Other disorders of brain in diseases classified elsewhere

Interventions

Intervention1: symptom based intervention: MRI will be done when patient is symptomatic Control Intervention1: Surveillance: MRI will be done every 6 monthly

Eligibility

Inclusion criteria

Inclusion criteria: Age more than equal to 18years Histopathological diagnosis of Glioblastoma. Disease clinico radiologically controlled at the completion of standard therapy. KPS more than or equal to 60 Signing informed consent

Exclusion criteria

Exclusion criteria: Patients without tissue diagnosis IDH mutant gliomas Patients with lesions indeterminate for recurrence Pediatric patients less than 18 years. Patients with confirmed recurrence. Patients unable to be part of their own informed decision making due to cognitive impairment.

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study will be the 2 year overall survival survival calculated from the date of diagnosis.Timepoint: 3 years	—

Secondary

Measure	Time frame
Progression free survival Rates of salvage treatment Quality of life Cost effectiveness analysisTimepoint: 3 years	—

Countries

India

Contacts

Public ContactDr Arpita Sahu

Tata Memorial Centre Mumbai

drarpitasahu@gmail.com02269537300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026